Last reviewed · How we verify

NCT07206732

IVC Ultrasound Versus Central Venous Pressure for Early Detection of Hypovolemia in Shock Patients

Not yet recruiting Last updated 19 November 2025
What this trial tests

trial testing Ultrasound-Guided Inferior Vena Cava Assessment in Shock in 80 participants. Not yet recruiting.

Timeline
15 December 2025
Primary endpoint
15 November 2026
15 December 2026

Quick facts

Lead sponsorAssiut University
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment80
Start date15 December 2025
Primary completion15 November 2026
Estimated completion15 December 2026
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

Adults 18 to 65, any sex, with Shock or Hypovolemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to compare ultrasound-guided inferior vena cava (IVC) assessment with central venous pressure (CVP) monitoring for the detection of hypovolemia in shock patients in the emergency department. The primary objective is to evaluate the diagnostic accuracy and clinical utility of IVC collapsibility index compared to CVP values in both early and post-resuscitation phases. The study will prospectively enroll shock patients, collect demographic and clinical data, and analyze the correlation between IVC and CVP measurements to determine their role in guiding fluid resuscitation and hemodynamic management.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Shock

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07206732.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing